Search - tctmd.com

Displaying 1 - 20 of 51

Sort: Relevancy | Date

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

Todd Neale

November 13, 2025

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

News Daily News

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Yael L. Maxwell

August 14, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Daily News

BMJ Investigation Revives Questions About PLATO, Ticagrelor

Todd Neale

December 20, 2024

News Conference News ESC 2024

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

Michael O'Riordan

September 02, 2024

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Conference News SCAI 2023

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

L.A. McKeown

May 22, 2023

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Todd Neale

November 21, 2022

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Conference News ACC 2022

Managing AF Patients Undergoing PCI—Some Lingering Questions

Michael O'Riordan

April 12, 2022

News Daily News

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Yael L. Maxwell

April 05, 2021

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

Caitlin E. Cox

October 15, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Daily News

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

L.A. McKeown

August 10, 2020

Advertisement

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

BMJ Investigation Revives Questions About PLATO, Ticagrelor

SENIOR-RITA Offers Rare Insights Into Best Care for Older NSTEMI Patients

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Repeat Revascularization Not Increased With Solo Ticagrelor: TWILIGHT Analysis

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

CV Care Around Noncardiac Surgery: New ESC Guidelines

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Managing AF Patients Undergoing PCI—Some Lingering Questions

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Analysis Supports Short DAPT Followed by P2Y12 Inhibitor Monotherapy After DES PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content